ReviewPediatric nephrology (Berlin, Germany)2026
Pediatric sepsis-associated acute kidney injury: leveraging pathophysiology for risk stratification and identification of treatable traits.
Review in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Sepsis-associated acute kidney injury (SA-AKI) is a common and morbid complication of pediatric critical illness that affects up to half of children with septic shock and is associated with independent risk for death and new disability. Once attributed primarily to systemic hypotension, SA-AKI is now recognized as a heterogeneous syndrome driven by diverse pathophysiologic mechanisms, including immune dysregulation, endothelial injury, microcirculatory alterations, mitochondrial dysfunction, metabolic reprogramming, and renin-angiotensin-aldosterone system (RAAS) derangement. This pathophysiologic complexity demands a precision medicine approach to improve risk stratification, diagnosis, and treatment. Precision medicine in SA-AKI relies on the identification of phenotypes, subphenotypes, endotypes, and treatable traits, distinct but complementary frameworks for characterizing patients by clinical features and underlying biology. Prognostic enrichment strategies, including novel biomarkers, clinical risk scores, and data-driven subphenotype models, are increasingly available to identify children at highest risk for persistent severe AKI, receipt of kidney replacement therapy, and death. Predictive enrichment strategies, designed to optimize therapy based on underlying pathophysiology, remain limited but are emerging. In this review, we summarize contemporary knowledge of pediatric SA-AKI pathophysiology, highlight clinical tools evaluated specifically in children, and outline a framework for translating mechanistic insights into actionable precision medicine strategies at the bedside.
Indexed as
Identifiers
42493645What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.